,92,93,94 Overexpressed in more than 50% of all human cancers and in 70% of the hematopoietic cancers, MYC is therefore the prime target of cancer therapeutic agents like JQ1.95 This evidence concerns the gene MYC and hematopoietic and lymphoid cell neoplasm.